1. Home
  2. CGBD vs ABUS Comparison

CGBD vs ABUS Comparison

Compare CGBD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$10.85

Market Cap

742.2M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
ABUS
Founded
2012
2005
Country
United States
United States
Employees
2500
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
742.2M
848.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
CGBD
ABUS
Price
$10.85
$4.56
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$12.92
$5.00
AVG Volume (30 Days)
513.8K
1.2M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
14.42%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$3.74
N/A
Revenue Next Year
$1.80
$239.71
P/E Ratio
$10.36
$5.28
Revenue Growth
N/A
128.21
52 Week Low
$10.62
$3.04
52 Week High
$14.32
$5.10

Technical Indicators

Market Signals
Indicator
CGBD
ABUS
Relative Strength Index (RSI) 38.77 57.10
Support Level $10.68 $4.16
Resistance Level $12.17 $4.60
Average True Range (ATR) 0.27 0.18
MACD -0.04 0.04
Stochastic Oscillator 16.82 67.81

Price Performance

Historical Comparison
CGBD
ABUS

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: